FDA approves EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture

Alternative Medicine
AmgenAmgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture.

Leave a Reply

Your email address will not be published. Required fields are marked *